Lantheus Holdings, Inc.
LNTHDrugs in Pipeline
11
Phase 3 Programs
7
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
2 upcoming, 1 past
LNTH Earnings Report
EPS Est: $1.11 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How LNTH's past catalysts played out
Florbetaben (BAY94-9172)
Alzheimer Disease
Sestamibi
Kawasaki Disease
[18F]florbetaben
Cardiac Amyloidosis
[18F]PI-2620
Alzheimer Disease
DEFINITY
Cardiac Disease
Flurpiridaz F18
Coronary Artery Disease
DEFINITY®
Cardiac Disease
LNTH2403 Phase 1 dose
Relapsed / Refractory Osteosarcoma
Peflutren Lipid Microsphere Injectable Suspension
Liver Disease
Technetium Tc99m Sestamibi
Kawasaki Disease
BMS747158
Ischemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Florbetaben (BAY94-9172) | Phase 3 | Alzheimer Disease | - | - |
Sestamibi | Phase 3 | Kawasaki Disease | - | - |
[18F]florbetaben | Phase 3 | Cardiac Amyloidosis | - | - |
[18F]PI-2620 | Phase 3 | Alzheimer Disease | - | - |
DEFINITY | Phase 3 | Cardiac Disease | - | - |
Flurpiridaz F18 | Phase 3 | Coronary Artery Disease | - | - |
DEFINITY® | Phase 3 | Cardiac Disease | - | - |
LNTH2403 Phase 1 dose | Phase 2 | Relapsed / Refractory Osteosarcoma | - | - |
Peflutren Lipid Microsphere Injectable Suspension | Phase 2 | Liver Disease | - | - |
Technetium Tc99m Sestamibi | Phase 2 | Kawasaki Disease | - | - |
BMS747158 | Phase 2 | Ischemia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Lantheus Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Lantheus Holdings, Inc.'s (LNTH) pipeline across Phase 3, Phase 2. Its lead program is Florbetaben (BAY94-9172) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lantheus Holdings, Inc.'s next FDA catalyst?→
Lantheus Holdings, Inc.'s (LNTH) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LNTH biotech catalysts?→
Add LNTH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lantheus Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.